Vittorio Silingardi
About
In The Last Decade
Vittorio Silingardi
27 papers receiving 595 citations
Peers
Comparison fields: 5 of 59
- Oncology 342
- Pathology and Forensic Medicine 202
- Genetics 137
- Molecular Biology 115
- Cancer Research 106
Countries citing papers authored by Vittorio Silingardi
This map shows the geographic impact of Vittorio Silingardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vittorio Silingardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vittorio Silingardi more than expected).
Fields of papers citing papers by Vittorio Silingardi
This network shows the impact of papers produced by Vittorio Silingardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vittorio Silingardi. The network helps show where Vittorio Silingardi may publish in the future.
Co-authorship network of co-authors of Vittorio Silingardi
This figure shows the co-authorship network connecting the top 25 collaborators of Vittorio Silingardi. A scholar is included among the top collaborators of Vittorio Silingardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vittorio Silingardi. Vittorio Silingardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 107 | |
| 2 | 2 | |
| 3 | 7 | |
| 4 | 18 | |
| 5 | 30 | |
| 6 | 41 | |
| 7 | A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). | 5 |
| 8 | 0 | |
| 9 | 2 | |
| 10 | Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL). | 10 |
| 11 | 37 | |
| 12 | 6 | |
| 13 | 19 | |
| 14 | 68 | |
| 15 | 58 | |
| 16 | Relationship between prognostic factors and therapy in high-grade non-Hodgkin's lymphomas over two decades. | 2 |
| 17 | 2 | |
| 18 | 4 | |
| 19 | 50 | |
| 20 | 15 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.